Literature DB >> 9002265

Experiences of photodynamic therapy in dermatology.

G Koderhold1, R Jindra, H Koren, G Alth, G Schenk.   

Abstract

From March 1988 to May 1994, 15 patients underwent the treatment protocol of superficial photodynamic therapy (PDT) in dermatological localized malignancies. Two tumours (one M. Queyrat of the penis, one basalioma) were treated primarily; the other 13 patients experienced relapses of underlying disease after treatment by surgery, radiotherapy or chemotherapy. Most of the patients (10/15) received doses of 2 mg Photosan III kg-1 body weight (BW), four received a lower dose of 1-1.5 mg kg-1 BW and one patient received 3 mg kg-1 BW. Only one remarkable side-effect (tachyarrhythmia) during Photosan III infusion occurred. All patients were treated by an argon dye laser system. The light dose was 200 J cm-2 (11 patients) and 150 J cm-2 (four patients). Complete response occurred in six lesions, including one M. Queyrat and five basaliomas. Two patients had significant partial response with distinct regression of tumour (one pretreated basalioma of the upper lip and one superficially spreading mesothelioma of the scrotum). Five patients (all basaliomas) demonstrated only local response and two patients gave no response (one basalioma, one melanoma metastasis). The results obtained from this small sample suggest the necessity of an optical dosimetric system. At present, PDT should be restricted for selected or pretreated cases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9002265     DOI: 10.1016/s1011-1344(96)07376-9

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  3 in total

Review 1.  Developing strategies to predict photodynamic therapy outcome: the role of melanoma microenvironment.

Authors:  Renzo Emanuel Vera; María Julia Lamberti; Viviana Alicia Rivarola; Natalia Belén Rumie Vittar
Journal:  Tumour Biol       Date:  2015-09-29

2.  Transcriptional activation of HIF-1 by a ROS-ERK axis underlies the resistance to photodynamic therapy.

Authors:  María Julia Lamberti; María Florencia Pansa; Renzo Emanuel Vera; Martín Ernesto Fernández-Zapico; Natalia Belén Rumie Vittar; Viviana Alicia Rivarola
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

3.  Evaluation of Ruthenium-Based Assemblies as Carriers of Photosensitizers to Treat Rheumatoid Arthritis by Photodynamic Therapy.

Authors:  Manuel Gallardo-Villagrán; Lucie Paulus; Jean-Louis Charissoux; Sylvain Sutour; Pascale Vergne-Salle; David Yannick Leger; Bertrand Liagre; Bruno Therrien
Journal:  Pharmaceutics       Date:  2021-12-07       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.